Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.37 |
| ▸ | CCKAR | P32238 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15002720 | 1.00 | GLP1R (0.59) | GLP1RNOD1SELPCCKARCCKBR | |
| SCHEMBL16867531 | 0.98 | GLP1R (0.56) | GLP1RNOD1SELPCCKARCCKBR | |
| SCHEMBL12673949 | 0.94 | GLP1R (0.56) | GLP1RNOD1SELPCCKARCCKBR | |
| SCHEMBL15002721 | 0.94 | GLP1R (0.57) | GLP1RNOD1SELPCCKARCCKBR | |
| SCHEMBL17131140 | 0.94 | GLP1R (0.57) | GLP1RNOD1SELPCCKARCCKBR | |
| SCHEMBL15358433 | 0.93 | GLP1R (0.66) | GLP1RNOD1CCKARCCKBR | |
| SCHEMBL15267729 | 0.93 | GLP1R (0.59) | GLP1RNOD1CCKARCCKBR | |
| SCHEMBL14819891 | 0.93 | GLP1R (0.49) | GLP1RNOD1SELP | |
| SCHEMBL15002704 | 0.92 | GLP1R (0.55) | GLP1RNOD1SELPCCKARCCKBR | |
| SCHEMBL17131127 | 0.92 | GLP1R (0.54) | GLP1RNOD1SELPCCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160347812-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-12-01 | — | — | US | disclosed |
| US-9486505-B2 | Glucagon analogues | NOVO NORDISK A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-9486506-B2 | Glucagon analogues | NOVO NORDISK A/S (DK) | 2016-11-08 | — | — | US | disclosed |
| US-20150374794-A1 | STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE | NOVO NORDISK A/S (DK) | 2015-12-31 | — | — | US | disclosed |
| US-20150182594-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-02 | — | — | US | disclosed |
| US-20130288958-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2013-10-31 | — | — | US | disclosed |
| US-8541368-B2 | Glucagon analogues | NOVO NORDISK A/S (DK) | 2013-09-24 | — | — | US | disclosed |
| US-20130079278-A1 | Novel Glucagon Analogues | NOVO NORDISK A/S (DK) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374794-A1 | STABLE, PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-AGONISTS FOR MEDICAL USE | GLP1R, GIPR, GCGR | GLP1R 1/4885NOD1 1398/4885SELP 655/4885 |
| US-20150182594-A1 | NOVEL GLUCAGON ANALOGUES | GLP1R, GCG, GCGR | GLP1R 1/4885NOD1 1939/4885SELP 1311/4885 |
| US-20130079278-A1 | Novel Glucagon Analogues | GLP1R, GCG, GCGR | GLP1R 1/4885NOD1 1939/4885SELP 1311/4885 |
| US-20130288958-A1 | Novel Glucagon Analogues | GLP1R, GCG, GCGR | GLP1R 1/4885NOD1 1939/4885SELP 1311/4885 |
| US-20160347812-A1 | Novel Glucagon Analogues | GLP1R, GCG, GCGR | GLP1R 1/4885NOD1 1939/4885SELP 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.